Netherlands· NL-bd1302665e8c

Braftovi 75 mg capsule, hard

A encorafenib product containing encorafenib, registered in Netherlands by Pierre Fabre Medicament. The same ATC class is registered in 14 of our 19 countries.

ATC L01EC03

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about encorafenibAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Encorafenib is registered in 14 of 19 countries.

Countries holding a registration under ATC L01EC03 (encorafenib), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
8 of them publish a price we can compare per daily dose

Search encorafenib products by name

Encorafenib · ATC L01EC03

14 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Icelandprice
Ireland
Japan
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of encorafenib costs, country by country.

Normalised to the WHO defined daily dose (0.45 g), so markets compare like for like.

1 market with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Encorafenib · price per daily dose (0.45 g)

USD · FX 28 Sept 2026

CH Switzerland$238.24

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: ENCORAFENIB
Manufacturer: Pierre Fabre Medicament
Country: Netherlands (NL)
ATC code: L01EC03
ATC class: Encorafenib
Defined daily dose: 0.45 g, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/18/1314

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

554 interactions on record for encorafenib.

Graded by severity as the source publishes them — 174 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check encorafenib against other medicines How interaction checks work

Encorafenib · interactions on record

554 records

174 severe
377 moderate
3 minor

Most severe, free to view

PapaverineA03AD01severe
CisaprideA03FA02severe
DolasetronA04AA04severe
AprepitantA04AD12severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Encorafenib in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All encorafenib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

Iceland · Braftovi
Liechtenstein · Braftovi
Norway · Braftovi

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/366fa606-078c-4a5e-bab6-d5d0b99c6245
GET /v1/drugs/366fa606-078c-4a5e-bab6-d5d0b99c6245?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Capsule, hard",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Encorafenib",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp121738",
  "excipients": [
    "AMMONIA (E 527)",
    "BARNSTEENZUUR (E 363)",
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "COPOVIDON (E 1208)",
    "CROSPOVIDON (E 1202)",
    "GELATINE (E 441)",
    "IJZEROXIDE GEEL (E 172)",
    "IJZEROXIDE ROOD  (E 172)",
    "IJZEROXIDE ZWART (E 172)",
    "IJZEROXIDE ZWART (E 172)",
    "MAGNESIUMSTEARAAT (E 470b)",
    "POLOXAMEER 188",
    "PROPYLEENGLYCOL (E 1520)",
    "SCHELLAK GLAZE, GEDEELTELIJK VERESTERD",
    "SILICIUMDIOXIDE (E 551)",
    "TITAANDIOXIDE (E 171)",
    "ZWARTE INKT"
  ],
  "substances": [
    "ENCORAFENIB"
  ],
  "leaflet_url": null,
  "authorised_at": "2018/09/20",
  "procedure_number": "EMEA/H/C/004580",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/18/1314",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about encorafenib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console